Inspire Medical Systems, Inc. Announces Second Quarter 2025 Financial Results and Updates 2025 Outlook

MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended June 30, 2025.

Recent Business Highlights

• Generated revenue of $217.1 million in the second quarter of 2025, an 11% increase over the same quarter last year
• Achieved gross margin of 84.0% in the second quarter of 2025
• Net loss was $3.6 million in the second quarter of 2025. Adjusted net income was $13.3 million
• Loss per share was $0.12 in the second quarter of 2025. Adjusted diluted earnings per share was $0.45
• Initiated the full launch of the Inspire V neurostimulation system in the U.S.
  
  

"The full launch of our FDA-cleared Inspire V system in the U.S. is an important milestone for Inspire. We have been receiving strong positive feedback from both surgeons and patients who value the simplified procedure and excellent patient outcomes enabled by this next generation technology," said Tim Herbert, Chairman and CEO of Inspire. "In the near future, we look forward to presenting the clinical evidence collected to date."

"The broad enthusiasm for Inspire V gives us confidence that it will be a growth engine for the Company. However, the U.S. commercial launch is progressing slower than expected, and the timeline to complete the full transition to Inspire V has been pushed forward, which will impact financial results for the year."

"Importantly, we believe the operational headwinds are temporary, and actions are underway to address them," continued Mr. Herbert. "We remain steadfast in our commitment to serving the many patients who struggle with untreated moderate to severe OSA, delivering strong patient outcomes and executing on our strategy to drive profitable growth and value creation for all stakeholders."

Second Quarter 2025 Financial Results

Revenue was $217.1 million for the second quarter, an 11% increase from $195.9 million in the corresponding prior year period. U.S. revenue for the quarter was $207.2 million, an increase of 10% as compared to the prior year quarter. Second quarter revenue outside the U.S. was $9.9 million, an increase of 23% as compared to the second quarter of 2024.

Gross margin was 84.0% for the second quarter of 2025 compared to 84.8% in the second quarter of 2024. The decrease is primarily due to a $2.1 million charge associated with excess components inventory related to Inspire IV.

Operating expenses were $185.7 million for the second quarter of 2025, as compared to $160.9 million in the corresponding prior year period, an increase of 15%. This increase primarily reflected ongoing investments in the expansion of the U.S. sales organization, patient marketing expenses, and general corporate costs, partially offset by a reduction in R&D. Operating expenses also included an additional one-time charge of $11.2 million of accelerated stock-based compensation expense for employees who are retirement eligible in accordance with changes to the Inspire incentive award plan upon the employee's death, disability, or retirement, and finally, $1.7 million in certain litigation-related legal expenses. These items do not reflect costs associated with our ongoing operations and a reconciliation table has been included at the bottom of this release.

Operating loss was $3.3 million for the second quarter of 2025, as compared to operating income of $5.1 million in the prior year period, a decrease of 165%.

Net loss was $3.6 million for the second quarter of 2025 as compared to a net income of $9.8 million in the corresponding prior year period. The net loss includes a $4.0 million non-cash impairment of a strategic investment. Adjusted EBITDA for the second quarter of 2025 was $44.1 million as compared to $38.7 million in the corresponding prior year period. The diluted net loss for the second quarter of 2025 was $0.12 per share, as compared to a net income of $0.32 per share in the prior year period. The adjusted net income for the second quarter of 2025 was $0.45 per share.

As of June 30, 2025, cash, cash equivalents, and investments were $410.7 million compared to $516.5 million on December 31, 2024.

Executive Retirement

"Randy Ban, our Executive Vice President of Patient Access and Therapy Development, recently notified us of his intention to retire on January 30, 2026. During his tenure, Randy has been one of Inspire's most influential leaders, and as our initial commercial leader, he played a significant role in advancing access to Inspire therapy and building a strong, mission-driven organization. We are grateful for Randy's many contributions and wish him the best in his retirement," concluded Mr. Herbert.

Full Year 2025 Guidance

Inspire currently anticipates full year 2025 revenue guidance to be in the range of $900 million to $910 million, which represents growth of 12% to 13% over full year 2024 revenue of $802.8 million. This compares to the prior guidance range of $940 to $955 million.

The company is maintaining its full year 2025 gross margin guidance of 84% to 86%.

Inspire anticipates diluted net income per share guidance for the full year 2025 to be in the range of $0.40 to $0.50. This compares to the prior guidance of $2.20 to $2.30 per share.

Webcast and Conference Call

Inspire's management will host a conference call after market close today, Monday, August 4, 2025, at 5:00 p.m. Eastern Time to discuss these results and answer questions.

To access the conference call, please preregister on https://register-conf.media-server.com/register/BI190b806d85f04e80ac078fecc3928846.

Registrants will receive confirmation with dial-in details.

A live webcast of the event can be accessed on https://edge.media-server.com/mmc/p/r7p84oir/. A replay of the webcast will be available on https://investors.inspiresleep.com starting approximately two hours after the event and archived on the site for two weeks.

About Inspire Medical Systems

Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire's proprietary Inspire therapy is the first and only FDA, EU MDR and PDMA-approved neurostimulation technology of its kind that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Use of Non-GAAP Financial Measures

This press release includes the non-GAAP financial measures of Adjusted net income, Adjusted earnings per share ("EPS"), Adjusted EBITDA, and Adjusted EBITDA margin, which differ from financial measures calculated in accordance with U.S. generally accepted accounting principles ("GAAP").

We define Adjusted net income as net income or loss, plus items that are not indicative of our ongoing operations. Net income is the most directly comparable GAAP financial measure to adjusted net income. Adjusted EPS is calculated as adjusted net income divided by the dilutive weighted average shares outstanding. Diluted EPS is the most directly comparable GAAP financial measure to adjusted EPS. We define Adjusted EBITDA as net income or loss, less interest income, plus interest expense, plus income tax expense, plus depreciation and amortization, plus stock-based compensation expense, plus litigation-related legal expenses and other non-operating expenses less non-operating income. Net income is the most directly comparable GAAP financial measure to Adjusted EBITDA. We define Adjusted EBITDA margin in this release as Adjusted EBITDA divided by revenue. Net income margin is the most directly comparable GAAP measure to Adjusted EBITDA margin. Reconciliations of these non-GAAP financial measures to their most directly comparable GAAP measures are included in this press release.

These non-GAAP financial measures are presented because we believe they are useful indicators of our operating performance. Management uses these measures principally as measures of our operating performance and for planning purposes, including the preparation of our annual operating plan and financial projections. We believe these measures are useful to investors as supplemental information and because they are frequently used by analysts, investors and other interested parties to evaluate companies in our industry. We also believe these non-GAAP financial measures are useful to our management and investors as a measure of comparative operating performance from period to period.

These non-GAAP financial measures should not be considered as an alternative to, or superior to, the most directly comparable GAAP financial measures, as measures of financial performance or cash flows from operations, as a measure of liquidity, or any other performance measure derived in accordance with GAAP, and they should not be construed to imply that our future results will be unaffected by unusual or non-recurring items. In addition, Adjusted EBITDA is not intended to be a measure of cash flow for management's discretionary use, as it does not reflect certain cash requirements such as tax payments, capital expenditures and certain other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our cash expenditures, cash requirements for working capital needs and cash costs to replace assets being depreciated and amortized. In evaluating our non-GAAP financial measures, you should be aware that in the future we may incur expenses that are the same as or similar to some of the adjustments in this presentation. Our presentation of non-GAAP financial measures should not be construed to imply that our future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on our GAAP results in addition to using non-GAAP financial measures on a supplemental basis. Our definition of these non-GAAP financial measures is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding full year 2025 financial outlook and our expectations regarding the launch of our Inspire V neurostimulation system, including the timeline to complete the full transition to that product. In some cases, you can identify forward-looking statements by terms such as ‘‘may,'' ‘‘will,'' ‘‘should,'' ‘‘expect,'' ‘‘plan,'' ‘‘anticipate,'' ‘‘could,'' "future," "outlook," "guidance," ‘‘intend,'' ‘‘target,'' ‘‘project,'' ‘‘contemplate,'' ‘‘believe,'' ‘‘estimate,'' ‘‘predict,'' ‘‘potential,'' ‘‘continue,'' or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words.

These forward-looking statements are based on management's current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, our history of operating losses and dependency on our Inspire therapy for revenues; commercial success and market acceptance of our Inspire therapy; our ability to achieve and maintain adequate levels of coverage or reimbursement for our Inspire therapy or any future products we may seek to commercialize; competitive companies, technologies and pharmaceuticals in our industry; our involvement in current or future legal disputes or regulatory proceedings; our ability to expand our indications and develop and commercialize additional products and enhancements to our Inspire therapy; future results of operations, financial position, research and development costs, capital requirements and our needs for additional financing; our ability to accurately forecast customer demand for our Inspire therapy and manage our inventory; our dependence on third-party suppliers, contract manufacturers and shipping carriers; consolidation in the healthcare industry; our ability to expand, manage and maintain our direct sales and marketing organization, and to market and sell our Inspire therapy in markets outside of the U.S.; risks associated with international operations; our ability to manage our growth; our ability to hire and retain our senior management and other highly qualified personnel; risk of product liability claims; our ability to address quality issues that may arise with our Inspire therapy; our ability to successfully integrate any acquired business, products, or technologies; changes in global macroeconomic trends; challenges experienced by patients in obtaining prior authorization, our ability to achieve and maintain adequate levels of coverage or reimbursement for our Inspire therapy; our business model and strategic plans for our products, technologies and business, including our implementation thereof; the impact of glucagon-like peptide 1 class of drugs on demand for our Inspire therapy; risks related to information technology and cybersecurity; our ability to commercialize or obtain regulatory approvals for our Inspire therapy, or the effect of delays in commercializing or obtaining regulatory approvals; and FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release can be found under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as updated in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 to be filed with the SEC, and as such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC's website at www.sec.gov and the Investors page of our website at www.inspiresleep.com. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, unless required by applicable law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Thus, one should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.

Investor & Media Contact

Ezgi Yagci

Vice President, Investor Relations

[email protected]

617-549-2443

Inspire Medical Systems, Inc. Consolidated Statements of Operations and Comprehensive Income (Loss) (unaudited) (in thousands, except share and per share amounts)
		Three Months Ended								Six Months Ended
		June 30,								June 30,
			2025				2024				2025				2024
Revenue		$	217,086			$	195,885			$	418,403			$	359,895
Cost of goods sold			34,672				29,843				65,381				54,600
Gross profit			182,414				166,042				353,022				305,295
Operating expenses:
Research and development			26,209				28,859				54,012				57,709
Selling, general and administrative			159,521				132,084				303,811				257,705
Total operating expenses			185,730				160,943				357,823				315,414
Operating (loss) income			(3,316	)			5,099				(4,801	)			(10,119	)
Other (income) expense:
Interest and dividend income			(4,486	)			(5,882	)			(9,552	)			(11,805	)
Interest expense			4				—				4				—
Other expense, net			3,498				135				2,920				195
Total other income			(984	)			(5,747	)			(6,628	)			(11,610	)
Income (loss) before income taxes			(2,332	)			10,846				1,827				1,491
Income taxes			1,260				1,053				2,427				1,703
Net income (loss)			(3,592	)			9,793				(600	)			(212	)
Other comprehensive income (loss):
Foreign currency translation gain (loss)			191				(39	)			(109	)			(173	)
Unrealized loss on investments			(22	)			(200	)			(31	)			(742	)
Total comprehensive income (loss)		$	(3,423	)		$	9,554			$	(740	)		$	(1,127	)
Net income (loss) per share:
Basic		$	(0.12	)		$	0.33			$	(0.02	)		$	(0.01	)
Diluted		$	(0.12	)		$	0.32			$	(0.02	)		$	(0.01	)
Weighted average shares outstanding:
Basic			29,506,807				29,728,849				29,604,043				29,672,006
Diluted			29,506,807				30,408,439				29,604,043				29,672,006

Inspire Medical Systems, Inc. Consolidated Balance Sheets (unaudited) (in thousands, except share and per share amounts)
		June 30, 2025				December 31, 2024
Assets
Current assets:
Cash and cash equivalents		$	106,927			$	150,150
Investments, short-term			193,968				295,396
Accounts receivable, net of allowance for credit losses of $1,229 and $880, respectively			137,687				93,068
Inventories, net			121,633				80,118
Prepaid expenses and other current assets			12,974				12,074
Total current assets			573,189				630,806
Investments, long-term			109,830				70,995
Property and equipment, net			85,274				71,925
Operating lease right-of-use assets			24,524				23,314
Other non-current assets			9,376				11,343
Total assets		$	802,193			$	808,383
Liabilities and stockholders' equity
Current liabilities:
Accounts payable		$	53,162			$	38,687
Accrued expenses			40,197				49,814
Total current liabilities			93,359				88,501
Operating lease liabilities, non-current portion			30,909				30,039
Other non-current liabilities			111				148
Total liabilities			124,379				118,688
Stockholders' equity:
Preferred Stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding			—				—
Common Stock, $0.001 par value per share; 200,000,000 shares authorized; 29,569,477 and 29,740,176 issued and outstanding at June 30, 2025 and December 31, 2024, respectively			29				30
Additional paid-in capital			969,903				981,043
Accumulated other comprehensive income			396				536
Accumulated deficit			(292,514	)			(291,914	)
Total stockholders' equity			677,814				689,695
Total liabilities and stockholders' equity		$	802,193			$	808,383

Inspire Medical Systems, Inc. Reconciliation of Non-GAAP Financial Measures (unaudited) (in thousands, except share and per share amounts) Reconciliation of GAAP Net Income (Loss) and Income per Share to Non-GAAP Adjusted Net Income and Adjusted Net Income per Share
		Three Months Ended							Six Months Ended
		June 30,							June 30,
			2025			2024				2025				2024
Net income (loss)		$	(3,592	)		$	9,793		$	(600	)		$	(212	)
Stock-based compensation expense(1)			11,155				—			11,155				—
Legal fees(2)			1,736				—			1,736				—
Other(3)			4,046				—			4,046				—
Adjusted net income (loss)		$	13,345			$	9,793		$	16,337			$	(212	)
Net income (loss) per share:
Basic		$	(0.12	)		$	0.33		$	(0.02	)		$	(0.01	)
Diluted		$	(0.12	)		$	0.32		$	(0.02	)		$	(0.01	)
Adjusted net income per share:
Basic		$	0.45			$	0.33		$	0.55			$	(0.01	)
Diluted		$	0.45			$	0.32		$	0.55			$	(0.01	)
Weighted average shares outstanding:
Basic			29,506,807				29,728,849			29,604,043				29,672,006
Diluted			29,506,807				30,408,439			29,604,043				29,672,006

⁽¹⁾ Represents accelerated stock-based compensation expense for certain employees who are retirement eligible in accordance with the implementation of changes to the treatment of equity awards under the Inspire Medical Systems, Inc. 2018 Incentive Award Plan upon the holder's death, disability, or retirement.

⁽²⁾ These costs represent legal-related expenses related to a civil investigative demand from the Department of Justice and a patent infringement suit that we filed against Nyxoah S.A. and its wholly-owned subsidiary, Nyxoah, Inc. These costs do not reflect costs associated with our normal ongoing operations.

⁽³⁾ Represents a non-cash impairment of a strategic investment, which does not reflect costs associated with our ongoing operations.

Reconciliation of GAAP Net Income (Loss) to Non-GAAP Adjusted EBITDA
		Three Months Ended								Six Months Ended
		June 30,								June 30,
			2025				2024				2025				2024
Net income (loss)		$	(3,592	)		$	9,793			$	(600	)		$	(212	)
Interest and dividend income			(4,486	)			(5,882	)			(9,552	)			(11,805	)
Interest expense			4				—				4				—
Income taxes			1,260				1,053				2,427				1,703
Depreciation and amortization			3,414				1,383				6,458				2,222
EBITDA			(3,400	)			6,347				(1,263	)			(8,092	)
Stock-based compensation expense(4)			41,724				32,322				72,780				58,644
Legal fees			1,736				—				1,736				—
Other			4,046				—				4,046				—
Adjusted EBITDA		$	44,106			$	38,669			$	77,299			$	50,552

⁽⁴⁾ Total stock-based compensation expense.

Reconciliation of GAAP Net Income Margin and Non-GAAP Adjusted EBITDA Margin
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2025			2024			2025			2024
Net income margin(5)		(2)	%		5	%		—	%		—	%
Interest and dividend income		(2)	%		(3)	%		(2)	%		(3)	%
Interest expense		—	%		—	%		—	%		—	%
Income taxes		1	%		1	%		1	%		—	%
Depreciation and amortization		2	%		1	%		2	%		1	%
Stock-based compensation expense(4)		18	%		16	%		16	%		16	%
Legal fees		1	%		—	%		—	%		—	%
Other		2	%		—	%		1	%		—	%
Adjusted EBITDA margin(6)		20	%		20	%		18	%		14	%

⁽⁴⁾ Total stock-based compensation expense.

⁽⁵⁾ Net income margin is calculated as net income (loss) divided by total revenue.

⁽⁶⁾ Adjusted EBITDA margin is calculated as Adjusted EBITDA divided by total revenue.